A citation-based method for searching scientific literature

Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, Christopher P Cannon, Bruce Neal, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull, George Capuano, Dick de Zeeuw, Tom Greene, Adeera Levin, Carol Pollock, Tao Sun, David C Wheeler, Yshai Yavin, Hong Zhang, Bernard Zinman, Norman Rosenthal, Barry M Brenner, Vlado Perkovic. Circulation 2019
Times Cited: 128



John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek, Michael Böhm, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer, Akshay S Desai, Mirta Diez, Jaroslaw Drozdz, Andrej Dukát, Junbo Ge, Jonathan G Howlett, Tzvetana Katova, Masafumi Kitakaze, Charlotta E A Ljungman, Béla Merkely, Jose C Nicolau, Eileen O'Meara, Mark C Petrie, Pham N Vinh, Morten Schou, Sergey Tereshchenko, Subodh Verma, Claes Held, David L DeMets, Kieran F Docherty, Pardeep S Jhund, Olof Bengtsson, Mikaela Sjöstrand, Anna-Maria Langkilde. N Engl J Med 2019
Times Cited: 1990




List of shared articles



Times cited

Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
Jonatan Barrera-Chimal, Ixchel Lima-Posada, George L Bakris, Frederic Jaisser. Nat Rev Nephrol 2022
6

Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials.
Juan Jose Garcia Sanchez, Juliette Thompson, David A Scott, Rachel Evans, Naveen Rao, Elisabeth Sörstadius, Glen James, Stephen Nolan, Eric T Wittbrodt, Alyshah Abdul Sultan,[...]. Adv Ther 2022
1

Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis.
Ning Li, Guowei Zhou, Yawei Zheng, Dan Lv, Xiangjun Zhu, Ping Wei, Min Zheng, Shijia Liu, Enchao Zhou, Wei Sun,[...]. PLoS One 2022
0

Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect.
Savina Nodari, Francesco Fioretti, Francesco Barilla. Heart Fail Rev 2022
0

Kidney and heart failure outcomes associated with SGLT2 inhibitor use.
Annemarie B van der Aart-van der Beek, Rudolf A de Boer, Hiddo J L Heerspink. Nat Rev Nephrol 2022
2

Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.
Bharathi Upadhya, Patrick M Kozak, Richard Brandon Stacey, Ramachandran S Vasan. Curr Hypertens Rep 2022
1

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.
Anna Norhammar, Johan Bodegard, Jan W Eriksson, Hermann Haller, Gerard C M Linssen, Amitava Banerjee, Avraham Karasik, Pavlos Mamouris, Navdeep Tangri, Tiago Taveira-Gomes,[...]. Diabetes Obes Metab 2022
0

Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Kåre I Birkeland, Johan Bodegard, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack,[...]. Diabetes Obes Metab 2021
22

Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
4

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes,[...]. Am Heart J 2021
32

The role of sodium glucose co-transporter inhibitors in heart failure prevention.
Vishnu Garla, Angela Subauste, Javed Butler, Lillian F Lien. J Diabetes Complications 2021
1

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji,[...]. Cardiovasc Diabetol 2021
22

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors.
Mustafa Kılıçkap, Meral Kayıkçıoğlu, Lale Tokgözoğlu. Anatol J Cardiol 2021
0

Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.
Ricardo Fontes-Carvalho, Diogo Santos-Ferreira, Itamar Raz, Nikolaus Marx, Frank Ruschitzka, Francesco Cosentino. Eur J Prev Cardiol 2021
8

Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years.
Claire A Lawson, Samuel Seidu, Francesco Zaccardi, Gerry McCann, Umesh T Kadam, Melanie J Davies, Carolyn Sp Lam, Hiddo L Heerspink, Kamlesh Khunti. EClinicalMedicine 2021
5

Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
Takashi Kadowaki, Fumiko Yamamoto, Yusuke Taneda, Yusuke Naito, Douglas Clark, Søren S Lund, Tomoo Okamura, Kohei Kaku. Expert Opin Drug Saf 2021
1

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J L Heersprink, Mikhail Kosiborod, Christoph Wanner, Eberhard Standl. Cardiovasc Diabetol 2021
3

Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility.
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén. Diabetes Res Clin Pract 2021
6

Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.
Gad Cotter, Beth A Davison, Christopher Edwards, Stefanie Senger, John R Teerlink, Faiez Zannad, Olav Wendelboe Nielsen, Marco Metra, Alexandre Mebazaa, Ovidiu Chioncel,[...]. Am Heart J 2021
0

Cardiovascular disease in diabetes, beyond glucose.
Robert H Eckel, Karin E Bornfeldt, Ira J Goldberg. Cell Metab 2021
18

Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient.
Paolo Severino, Andrea D'Amato, Silvia Prosperi, Bettina Costi, Danilo Angotti, Lucia Ilaria Birtolo, Cristina Chimenti, Carlo Lavalle, Viviana Maestrini, Massimo Mancone,[...]. Heart Fail Rev 2021
5

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Giuseppe Bellastella, Maria Ida Maiorino, Katherine Esposito. Cardiovasc Diabetol 2021
5